189261-10-7
189261-10-7 結(jié)構(gòu)式
基本信息
Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-108831A | 那他珠單抗 Natalizumab (Anti-CD49d) | 189261-10-7 | 5 mg | 2400元 |
| 2026/06/05 | HY-108831A | 那他珠單抗 Natalizumab (Anti-CD49d) | 189261-10-7 | 10 mg | 3900元 |
| 2026/06/05 | HY-108831 | 那他珠單抗 Natalizumab | 189261-10-7 | 1 mg | 1600元 |
常見問題列表
那他珠單抗是一種重組的人源化單克隆抗體，與 α4β1-整聯(lián)蛋白 (α4β1-integrin) 結(jié)合并阻斷其與血管細(xì)胞粘附分子 1 (VCAM-1) 的相互作用。那他珠單抗可用于復(fù)發(fā)緩解型多發(fā)性硬化癥和克羅恩氏病的研究， 也可阻止淋巴細(xì)胞進(jìn)入中樞神經(jīng)系統(tǒng)，從而防止急性脫髓鞘復(fù)發(fā)。
Natalizumab, a recombinant, humanized antibody, binds to α4β1-integrin and blocks its interaction with VCAM-1. As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions. Natalizumab may also inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes already present in the CNS, by interrupting the interactions between α4-integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin.
Natalizumab binds rapidly and with high affinity to α4-integrin. Maximal binding (≥80% saturation), measured in vitro on isolated lymphocyte membranes, occurred 24 hours after intravenous (IV) doses of natalizumab 1 mg/kg to 6 mg/kg.